Home
·
Merck Group
·
Contact
·
Deutsch
·
Sitemap
·
Search
Sitemap
Merck 2010 at a glance
Development 2001-2010
Key events of 2010
About Merck
History
Today and the future
Letter from Karl-Ludwig Kley
Executive Board
Financial calendar
Corporate governance
Corporate governance report
Merck KGaA
Compensation report
Executive Board
Supervisory Board
Ownership of shares
Corporate governance practices
Principles
Values and compliance
Procedures of the corporate bodies
Executive Board
Supervisory Board
Board of Partners of E. Merck OHG
Report of the Supervisory Board
Objectives of the supervisory board
Merck in the capital market
Share price development
Share data
Shareholder structure
Estimates
Capital and shares
Bond issue
Management Report
Economic situation
Financial position and results of operations
Business development
Business sectors
Regions
Acquisitions
Total assets
Free cash flow
Capital spending
Key financial performance indicators
Value added
Corporate Responsibility
Employees
International human resources work
Diversity in the workforce
Products and the environment
Society
Corporate and Other
Risk report
Business-related risks
Financial risks
Legal risks
Human resource risks
Information technology risks
Environmental and safety risks
Report on expected developments
Global economy
Merck
Pharmaceuticals
Chemicals
Subsequent events
Merck Serono
Business development
Regions
Therapeutic areas
Oncology
Neurodegenerative Diseases
Fertility
Endocrinology
CardioMetabolic Care and General Medicine
Research and development
Overview compounds
Cooperations
Oncology
Neurodegenerative Diseases
Fertility
Autoimmune and Inflammatory Diseases
Endocrinology
Consumer Health Care
Business development
Brands
Regions
Merck Millipore
Business development
Bioscience
Lab Solutions
Process Solutions
Performance Materials
Business development
Liquid Crystals
Pigments / Cosmetics
Financial Statements
Income Statement
Balance Sheet
Segment Reporting
Divisions
Regions
Cash Flow Statement
Free Cash Flow
Comprehensive Income
Changes in Net Equity
Notes
Scope of consolidation
Accounting policies
Notes to the
income statement
Sales
Royalty, license and commission income
Cost of sales
Marketing and selling expenses
Royalty, license and commission expenses
Administration expenses
Other operating expenses and income
Research and development
Amortization of intangible assets
Investment result
Exceptional items
Financial result
Income tax
Non-controlling interest
Earnings per share
Notes to the balance sheet
Cash and cash equivalents
Marketable securities
Trade accounts receivable
Inventories
Other assets
Tax receivables
Assets held for sale and liabilites
Intangible assets
Property, plant and equipment
Investments at equity
Non-current financial assets
Financial assets covering pension obligations
Financial liabilities
Trade accounts payable
Other liabilities
Tax liabilities
Provisions
Provisions for pensions
Net equity
Notes to the segment reporting
Notes to the cash flow statement
Net cash flows from operating activities
Net cash flows from investing activities
Net cash flows from financing activities
Cash and cash equivalents
Free cash flow
Other disclosures
Derivative financial instruments
Management of financial risks
Other disclosures on financial instruments
Contingent liabilities
Other financial obligations
Personnel expenses
Material costs
Auditors' fees
Corporate governance
Companies opting for exemption
Related-party disclosures
Compensation of the corporate bodies
Preparation and approval
Subsequent events
List of shareholdings
Auditor's Report
SERVICES
Recommend page
Print page
Order online
Glossary
Downloads
CHART GENERATOR
Important key figures
Merck 2010 at a glance
Corporate governance
Merck in the capital market
Management Report
Merck Serono
Consumer Health Care
Merck Millipore
Performance Materials
Financial Statements
Notes
made by Nexxar - your next annual report online!, Vienna - Austria
